Groundbreaking Blood-Based Test for Colorectal Cancer
GC Genome, a standout in the field of clinical genomics and liquid biopsy, has made waves with its recent publication in a prestigious medical journal. Their collaborative research with renowned expert Professor Byeon, Jeong-Sik at Asan Medical Center has been recognized in The American Journal of Gastroenterology. This significant milestone showcases the potential of their innovative approach to colorectal cancer screening.
Exciting Developments in Colorectal Cancer Screening
The cutting-edge AI-driven technology utilized in their multi-cancer early detection (MCED) test, known as ai-CANCERCH, forms the backbone of this study. This development aims to provide an alternative to traditional colonoscopy and stool-based screening methods, positioning it as a promising solution for early colorectal cancer detection.
Study Details and Enrollment Results
In this extensive research project, a total of 1,677 participants were enrolled, comprising 302 individuals diagnosed with colorectal cancer (CRC), 108 with advanced adenomas (AA), and 1,267 who were considered healthy controls with normal colonoscopy results. By leveraging cfDNA fragmentomic signatures through low-coverage whole-genome sequencing (Lc-WGS) coupled with a proprietary AI algorithm, the test offers impressive sensitivity for uncovering early-stage cancers.
Key Study Outcomes
The findings indicate remarkable sensitivity and specificity levels for early detection of colorectal cancer:
- CRC sensitivity reached an impressive 90.4%.
- Specificity in individuals identified as having normal colonoscopy stood at 94.7%.
- Sensitivity rates varied across CRC stages: 84.2% for stage I, 85.0% for stage II, 94.4% for stage III, and a perfect 100.0% for stage IV.
- The test also demonstrated a sensitivity of 90.0% for T1N0 lesions, which are suitable for endoscopic resection.
- A sensitivity of 58.3% for advanced adenomas was also observed.
These outcomes remained consistent irrespective of various factors, including CRC location, patient age, and advanced adenoma position. These results strongly position the test as a reliable cfDNA-based alternative for colorectal cancer screening and early preventive measures.
Impact for the Future
A spokesperson from GC Genome shared insights on the significance of their work: "Detecting colorectal cancer alongside precancerous lesions marks a crucial step forward in preventive medicine. With this study published in a leading gastroenterology journal, GC Genome is committed to continuing global collaborations and expanding screening applications. This research illuminates our path forward in cancer diagnostics."
About ai-CANCERCH
Debuted in September of the previous year, ai-CANCERCH represents a sophisticated AI-powered test for early cancer detection. It requires just 10 mL of blood and is designed to identify signals linked to various cancers, with plans to expand its capability from six to ten detectable cancer types, which include colorectal, lung, esophageal, liver, ovarian, pancreatic, biliary, breast, gastric, and head-and-neck cancers. This upgrade is slated for release early in the coming year.
About GC Genome
Founded in 2013, GC Genome is dedicated to innovating diagnostics aimed at enhancing medical care through genetic testing services across oncology, pre-and-neonatal care, and more. The company, which operates a CAP-accredited lab, emphasizes research and development with strong global partnerships. Their impressive growth trajectory showcases a commitment to expanding testing capabilities and improving patient outcomes.
Frequently Asked Questions
What is the main focus of GC Genome's recent study?
The study focuses on a blood-based colorectal cancer screening method that utilizes AI technology for early detection.
What are the key findings of the study?
The study showed 90.4% sensitivity for CRC detection and high specificity in healthy individuals, making it a promising screening tool.
How does the ai-CANCERCH test work?
The ai-CANCERCH test analyzes cfDNA fragmentomic signatures via low-coverage whole-genome sequencing and AI algorithms to detect cancer early.
What future developments are expected for ai-CANCERCH?
The test is expected to expand from detecting six to ten types of cancer by early next year.
What is GC Genome's mission?
GC Genome aims to connect healthcare and genetic diagnosis to enhance patient lives through personalized treatment solutions.
